India Oncology NGS Market Growth & Trends

The India oncology NGS market size is expected to reach USD 70.59 million by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 14.6% from 2020 to 2027. Companion diagnostic assays are a crucial part of personalized medicine. Key drivers that can be attributed to the market expansion include the growing adoption of sequencing platforms for cancer diagnosis as a consequence of a significant reduction in the cost of installation.

Simple NGS (next-generation sequencing) workflows, coupled with continued cost reductions in instruments as well as reagents, can be attributed to the increasing adoption of this technology. Moreover, there are other significant growth trends witnessed in the market such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. In addition, a rise in the incidence of cancer in India is anticipated to be a significant driver of the market.

For instance, the National Cancer Registry Program by the Indian Council of Medical Research (ICMR) states that more than 1,300 Indians die due to some form of cancer every day in India. This is mainly due to poor diagnosis, prevention, and treatment of the disease. The time and cost accuracy of NGS-based cancer diagnostics is anticipated to improve the cancer diagnostics landscape in India, and thus is a high impact rendering driver of the market. Moreover, the ability of NGS-based tumor analysis to predict a patient’s response for targeted therapy is expected to boost market growth.

Several Indian companies, such as Premas Life Sciences Pvt. Ltd., are distributors of Illumina in India. Premas Life Sciences Pvt. Ltd. and Medgenome Labs are two of the largest players in the Indian market.

India Oncology NGS Market Report Highlights

  • By technology, the targeted and gene panel sequencing segment held the largest market share in 2019 as targeted panels serve as a cost-effective technology for the provision of clear and actionable information to the physicians. The hybridization-based technology dominated the market for oncology research in NGS owing to high throughput
  • The research studies application segment occupied a major share in the market in 2019 owing to the extensive use of NGS technology for oncology research. The diagnostics and screening application segment is expected to expand at the fastest CAGR over the forecast period owing to a rise in the adoption of NGS-based molecular diagnosis of cancer
  • By product, the platforms and related products segment held the largest revenue share in 2019. Ongoing studies to assess the performance of various targeted NGS gene panels with respect to their technical features and clinical utility are driving the adoption rate in this segment
  • The sequencing workflow segment is expected to register the fastest growth rate throughout the forecast period as it is the most critical phase in the workflow
  • By end-use, the clinical research segment is expected to expand at the fastest CAGR from 2020 to 2027. The segment is expected to witness significant growth in the future owing to the use of NGS in cancer research and more specifically in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that contribute to tumorigenesis